Abbott/Triangle To File Coactinon In 1999 Under $335 Mil. Co-Promotion
Executive Summary
Triangle Pharmaceuticals could file an NDA for its anti-HIV product Coactinon (emivirine) by year-end under a $335 mil. co-promotion agreement with Abbott announced June 3.
You may also be interested in...
Triangle Coviracil NDA Slated For September; Abbott Bows Out As Partner
Triangle Pharmaceuticals will file an NDA for Coviracil in September without a marketing partner following the reacquisition of rights to the nucleoside reverse transcriptase inhibitor from Abbott
Triangle Coviracil NDA Slated For September; Abbott Bows Out As Partner
Triangle Pharmaceuticals will file an NDA for Coviracil in September without a marketing partner following the reacquisition of rights to the nucleoside reverse transcriptase inhibitor from Abbott
Triangle Coviracil Study Completion Funded Via $100 Mil. Equity Facility
Triangle Pharmaceuticals' $100 mil. equity facility appears to be sufficient to finance the company until it completes clinical development of the HIV nucleoside analogue Coviracil (emtricitabine).